WebMar 15, 2007 · Biotheranostics, Inc. is a provider established in San Diego, California operating as a Clinical Medical Laboratory. The NPI number of this provider is … WebApr 19, 2024 · Biotheranostics Inc. has agreed to pay $2 million to resolve allegations that it submitted and caused the submission of false claims to Medicare for Breast Cancer Index (BCI) tests that were not reasonable and necessary for the diagnosis and treatment of breast cancer, the Department of Justice announced today. Biotheranostics is a …
San Diego Laboratory Agrees to Pay $2 Million to Settle False …
WebbioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, today announced clinical study findings that link CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site … WebNov 2, 2011 · bioTheranostics Tim Schofield Tel: + 1 858 587 5890 [email protected] bioMerieux Koren Wolman-Tardy Tel: + 011 33 6 13 94 51 14 [email protected] SOURCE bioTheranostics, Inc. citichurch
Breast Cancer Index Test
WebJul 18, 2016 · Au 30 juin 2016, le chiffre d’affaires de bioMérieux a atteint 1 001 millions d’euros contre 933 millions d’euros au 30 juin 2015, soit une hausse à données publiées de 7,2 %, intégrant des effets de change négatifs de 26 millions d’euros environ, auxquels s’ajoute un effet de périmètre lié à la déconsolidation de ... WebCancerTYPE ID is performed, reported and billed separately by Biotheranostics, Inc., an independent CLIA-licensed and CAP-accredited reference laboratory. The test uses quantitative RT-PCR to measure the expression of 92 genes in the patient’s specimen and classifies the tumor by matching the gene expression profile to a database of more than ... citi chief credit officer